MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jan 6, 2020 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Acrotech Biopharma Inc.
- Interventions being studied
- Drug: Belinostat, Carboplatin, Paclitaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- A histologically or cytologically confirmed diagnosis of Stage IV (M1a or M1b) NSCLC. Patients with mixed non-small cell histologies are eligible
- No prior chemotherapy for the treatment of advanced NSCLC
- Prior adjuvant therapy for early stage lung cancer is allowed if completed ≥ 12 months prior to enrollment
- Age \>= 18 years
- Adequate organ function
- Any treatment with investigational agent must have completed ≥ 4 weeks prior to enrollment
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Negative pregnancy test for women of childbearing potential.
- Patients with brain metastases allowed if:
- Directed local therapy was completed 2 weeks prior to enrollment;
- There is no evidence of disease progression and;
- Steroids are not required
- Patients with mixed tumors of small cell features
- Known infection with HIV, hepatitis B or hepatitis C
- Baseline prolongation of QT/QTcF interval or required concomitant medication that may cause Torsade de Pointes
- Preexisting ≥Grade 2 neuropathy
- Valproic acid treatment within 2 weeks of study enrollment
- Systemic steroids, for any indication, stabilized at \>10 mg/day prednisone
- Known allergy or hypersensitivity to any component of belinostat, paclitaxel or carboplatin
- Co-existing active infection or any other uncontrolled medical condition likely to interfere with trial procedures
- Active concurrent malignancy (except basal cell carcinoma or cervical intraepithelial neoplasia, other potentially cured malignancy that has been in remission for five years or prior adjuvant therapy for early stage lung cancer that is completed ≥ 12 months ago)
- Pregnant or breast-feeding women
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Clearview Cancer Institute (CCI)Huntsville, Alabama
- Sarcoma Oncology CenterSanta Monica, California
- University Cancer InsituteBoynton Beach, Florida
- Washington University School of MedicineSt Louis, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 6, 2020. Always confirm current availability with the study team.